The Asia Pacific pancreatic cancer therapeutics & diagnostics market size was USD XX Billion in 2022 and is likely to reach USD XX Billion by 2031, expanding at a CAGR of 6.4% during 2023–2031. Growth of the market is attributed to the high demand for diagnostic testing and treatment. Pancreatic cancer starts from the pancreatic tissues.
The pancreas produces enzymes that aid digestion and regulate blood sugar levels. The pancreatic cancer rapidly stretches to surrounding organs. People with a pancreatic cyst or a family history of pancreatic cancer are often detected at an early stage. Diabetes is the most prevalent symptom of pancreatic cancer, followed by weight loss and discomfort in the upper abdomen that travels to the back.
The market for pancreatic cancer diagnostics is predicted to develop faster as the prevalence of pancreatic cancer rises. Furthermore, rising illness awareness and concern, increasing healthcare spending, technical breakthroughs and new product innovation, are estimated to propel the pancreatic cancer diagnostics market during the forecast period.
The Covid-19 pandemic affected the demand and supply of Asia Pacific pancreatic cancer therapeutics & diagnostics market. Lockdown across the globe, supply chain disorders, and oscillating supply of raw materials forced manufacturers to shut down production leading to unfortunate decline in market growth. Launch of vaccines to combat the Covid-19 pandemic is expected to contribute to the market growth over the forecast period.
Market Trends, Drivers, Restraints, and Opportunities
-
Increasing demand for diagnostic testing and treatment is expected to propel the market in the coming years.
-
Increasing healthcare expenditure is key factor fueling the market during the forecast period.
-
The high cost of treatment and diagnostics, as well as therapy-related adverse effects, are projected to hinder the market growth.
-
Limited treatment options act as major challenge that can hamper the market expansion during the forecast period.
-
Technological advancements and medicinal improvements are anticipated to offer immense opportunities for the market players.
Scope of Pancreatic Cancer Therapeutics & Diagnostics Market Report
The report on the Asia-Pacific pancreatic cancer therapeutics & diagnostics market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
|
Attributes
|
Details
|
|
Report Title
|
Pancreatic Cancer Therapeutics & Diagnostics Market - Asia-Pacific Industry Analysis, Growth, Share, Size, Trends, and Forecast
|
|
Base Year
|
2022
|
|
Historic Data
|
2016–2021
|
|
Forecast Period
|
2023–2031
|
|
Segmentation
|
Cancer Type (Exocrine and Endocrine), Treatment (Surgery, Chemotherapy, Radiation Therapy, and Targeted Therapy), Diagnostics (Imaging, Biopsy, Endoscopy, and Other diagnostic tests)
|
|
Geographical Scope
|
China, Japan, India, Australia, South Korea, and Rest of Asia-Pacific.
|
|
Report Coverage
|
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast
|
|
Key Players Covered in the Report
|
Eli Lilly and Company, Bristol-Myers Squibb, Pfizer Inc, Novartis, and F. Hoffman-La Roche AG.
|
Pancreatic Cancer Therapeutics & Diagnostics Market Segment Insights
The exocrine segment is projected to hold a major market share
On the basis of cancer type, the Asia Pacific pancreatic cancer therapeutics & diagnostics market is bifurcated into exocrine and endocrine. The exocrine segment is expected to represent a key share of the market during the forecast period owing to rising number of patients having exocrine type of cancer. Exocrine cancer accounts for around 93 percent of pancreatic cancer.
They begin in the pancreas' exocrine cells, which generate enzymes that aid digestion. Exocrine pancreatic cancer arises from the exocrine gland and ducts of the pancreas, which are made up of exocrine cells. In the duodenum, the exocrine gland secretes enzymes that aid in the breakdown of carbs, lipids, proteins, and acids.
The radiation therapy segment is anticipated to expand at a high CAGR
Based on treatment, the Asia Pacific pancreatic cancer therapeutics & diagnostics market is segregated into surgery, chemotherapy, radiation therapy, and targeted therapy. The radiation therapy segment is expected to represent a key share of the market during the forecast period. Radiation treatment helps to slow the growth of pancreatic cancers and potentially decrease them.
The imaging segment is expected to grow at a rapid pace
On the basis of diagnostics, the market is divided into imaging, biopsy, endoscopy, and others. The imaging segment is expected to constitute a key share of the market during the forecast period owing to technological developments of imaging techniques with respect to pancreatic cancer. It is one of the deadliest malignancies, and is a serious public health issue in the twenty-first century.
Because early-stage illness is typically quiet or appears with non-specific symptoms that go unnoticed, diagnosis is almost reliant on imaging modalities. Medical imaging advancements have enhanced the capacity to diagnose and treat young diseases like cancer.
Computed tomography (CT) is the most regularly utilized imaging tool for pancreatic cancer detection and staging. Imaging enables doctors to detect cancers in their early stages, resulting in better patient outcomes. As diseases are most curable when identified early, this efficient technology has the potential to save lives.
China is expected to dominate the market
On the basis of geography, the Asia-Pacific pancreatic cancer therapeutics & diagnostics market is categorized as China, Japan, India, Australia, South Korea, and Rest of Asia-Pacific. China is anticipated to dominate the market at a high CAGR during the forecast period.
Factors such as high prevalence of pancreatic cancer, substantial unmet requirements, and presence of emerging countries like India and China in the region are anticipated to boost the market.
Segments
The Asia-Pacific pancreatic cancer therapeutics & diagnostics market has been segmented on the basis of
Cancer Type
Treatment
- Surgery
- Chemotherapy
- Radiation therapy
- Targeted therapy
Diagnostics
- Imaging
- Biopsy
- Endoscopy
- Other diagnostic tests
Geography
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia-Pacific.
Key Players
Competitive Landscape
Key players competing in the Asia-Pacific pancreatic cancer therapeutics & diagnostics market include Eli Lilly and Company, Bristol-Myers Squibb, Pfizer Inc, Novartis, and F. Hoffman-La Roche AG. Some of these players are using several market strategies such as mergers, acquisitions, partnerships, collaborations, capacity expansion, and product launches to enhance their market shares.
Request For Customization
Enquiry Before Buying
Speak With Analyst
